Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$40.04 (+0.15%) as of
Key statistics
- Market cap
- 17.76B
- P/E (TTM)
- 42.15
- Forward P/E
- 26.11
- EPS (TTM)
- 0.950
- Dividend yield
- 0.00%
- 52-week range
- 23.020 – 80.650
- Beta
- 0.01
- Revenue (TTM)
- 1.7B
- Profit margin
- 21.56%
- Analyst target
- HK$63.08
- Volume
- 2.42M
About Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; engages in breeding and selling animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; engages un utilizing the Group's own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and engages in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial. The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Beijing, China
- Employees
- 1,922
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.